Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
US FDA approves use of Sanofi's meningococcal vaccine in infants
07:37am, Tuesday, 27'th May 2025
French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.
C4X Discovery receives latest milestone payment from Sanofi
03:00am, Tuesday, 27'th May 2025
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme
Sanofi, VNVC launch vaccine factory in Vietnam
02:17am, Tuesday, 27'th May 2025
Sanofi and Vietnam Vaccine JSC, or VNVC, on Tuesday launched a vaccine manufacturing facility in Vietnam, aimed at producing vaccines for domestic use and export.
Press Release: Sanofi completes acquisition of DR-0201
01:00am, Tuesday, 27'th May 2025
Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private c
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of V
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
05:30pm, Thursday, 22'nd May 2025
MORRISTOWN, N.J. , May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboratio
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
11:15am, Thursday, 22'nd May 2025
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
Sanofi to Buy Vigil Neuroscience for About $470 Million
07:59pm, Wednesday, 21'st May 2025
Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer's disease to the French pharmaceutical company's pipe
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
07:30pm, Wednesday, 21'st May 2025
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the fi
Sanofi to acquire Vigil Neuroscience in $470 million deal
07:29pm, Wednesday, 21'st May 2025
Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innov
French finance minister criticises Sanofi's $20 bln USA investment decision
12:55pm, Thursday, 15'th May 2025
France's finance minister criticised on Thursday a decision by French drugmaker Sanofi to invest at least $20 billion in the United States through to 2030, as France aims to get more companies investi
Sanofi to invest at least $20 billion in the US through 2030
12:42pm, Wednesday, 14'th May 2025
French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through 2030, which includes an increase in research and development spending and the allocation
